Compare CVS Health Corp (CVS) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Oatly Group AB - ADR — how do they compare? CVS Health Corp trades at $86.82 (market cap $112.49B), while Oatly Group AB - ADR trades at $11.93 (market cap $330.93M). The key difference: CVS Health Corp is far larger — about 339.9× Oatly Group AB - ADR's market cap, and CVS Health Corp pays a 3.02% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Oatly Group AB - ADR for 18 Days on average.
| CVS | OTLY | |
|---|---|---|
Market Cap | $112.49B | $330.93M |
Volume | 8,467,392 | 44,023 |
Sector | Health | Consumer Staples |
52-Week High | $110.60 | $15.91 |
52-Week Low | $70.08 | $8.03 |
Typical Hold Time | 83 Days | 18 Days |
Enterprise Value | $174.83B | $835.34M |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Oatly (OTLY) trades at $10.38, down 1.24% today, with a mixed technical picture showing bearish moving averages but oversold RSI levels. The company continues to report revenue growth ($862M in 2025) but remains unprofitable with a -17.72% net margin. Recent Q2 2026 results showed a revenue beat and improved guidance, driving positive sentiment. Analyst consensus is divided with a $12.28 price target, while cash flow trends show gradual operational improvement despite negative net income.
The outlook remains challenging as Oatly works toward profitability amid high debt levels and negative cash flow. Investment opportunity exists if margin improvements continue and the company achieves positive EBITDA. Key risks include execution on cost controls, competitive pressures in plant-based beverages, and the sustainability of recent revenue growth momentum in a challenging consumer environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
